Overview

A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL

Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
0
Participant gender:
All
Summary
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Cooperative Study Group A for Hematology
Criteria
Inclusion Criteria:

- Patients with relapsed/resistant acute lymphoblastic leukemia

- Patients must be between 15 and 65 years of age.

- Estimated life expectancy of more than 3 months

- ECOG performance status of 2 or lower, Karnofsky scale > 60 (see appendix I)

- Adequate cardiac function (EF>45%) on echocardiogram or MUGA scan

- Adequate kidney function (estimated Ccr >50 ml/min)

Exclusion Criteria:

- Patients with CNS involvement of leukemic blasts will not be excluded.

- Patients with extramedullary relapse(s) only will be excluded.